ISHLT Survey of Cytomegalovirus (CMV) Prevention Strategies in Heart Transplant Recipients (ISHLT 2026) - Feb 2, 2026 - Abstract #Pub #1455; Pres time: Apr 24, 2026; 04:30 PM - 05:30 PM; Location: Poster Hall; Board #001; "However, 2 centers used (val)ganciclovir for 3 or 6 months...Letermovir substitution for cytopenia was employed in US, Canadian, Japanese, and Hungarian programs.10/10 centers initiated CMV prophylaxis following augmented immunosuppression, particularly after antithymocyte globulin for up to 3 months for both CMV R+ and D+/R-, however, practices after rituximab or high-dose steroids were variable...UP is universally applied in D⁺/R⁻, variably used in R⁺, and omitted in D⁻/R⁻ recipients. Letermovir adoption for cytopenia reflects evolving practice toward improved tolerability."
Clinical • Cytomegalovirus Infection • Hematological Disorders • Transplantation
|
|
A. Iizawa 1; R. Dhingra 2; T. Claridge 3; J. Schaenman 4; A. Zuckermann 5; Y. Natori 6
|